Lars Wegner News Today

Investegate announcements from Evaxion Biotech, Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for melanomaAnnounced gonorrhea as second bacterial product

Investegate announcements from Evaxion Biotech, Evaxion Biotech A/S Announces Executive Management Changes 

Investegate announcements from Evaxion Biotech, Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital

COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-powered

Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving

Investegate announcements from Evaxion Biotech, Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update

Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis' ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

COPENHAGEN, Denmark, March 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now...